No relevant information is available at the moment.
A study in human burn patients demonstrated that the IGLJ3 exhibits an age-dependent, interactive effect with burn injury, showing a significant difference between patients and controls specifically at the middle stage (11–49 days post-injury) but not at the early stage [Zhou et al. DOI:10.1073/pnas.1002757107].